Welcome to our dedicated page for KORU Medical Systems SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
KORU Medical Systems, Inc. (KRMD) reported that its Chief Commercial Officer, Adam R. Kalbermatten, purchased 32,000 shares of common stock on September 8, 2026, in an open-market or private transaction at $3.16 per share, bringing his directly held stake to 394,017 shares. The filing indicates this trade was not made pursuant to a Rule 10b5-1 trading plan, and it includes a standard disclaimer that the reporting person is not admitting beneficial ownership beyond what is required.
KORU Medical Systems, Inc. reports a governance change approved by its Board of Directors effective August 13, 2026. The company amended Section 3.05 of its Amended and Restated By-laws so that, consistent with the Delaware General Corporation Law, the authority to remove any director rests exclusively with shareholders through an affirmative vote of holders of a majority of the company’s outstanding shares.
The Board states it has never voted to remove a director and has no intention or agreement to do so. The amendment is filed as an exhibit to this report.
KORU Medical Systems, Inc. reported that Chief Commercial Officer Adam R. Kalbermatten had 75,000 shares of common stock delivered on July 28, 2026 upon vesting of previously granted restricted stock units, each converting into one share. On the same date, 25,483 shares were withheld at $4.26 per share to satisfy tax obligations related to the vesting. The transactions were reported as direct holdings and not under a Rule 10b5-1 trading plan.
KORU Medical Systems reported strong top-line growth for the quarter ended June 30, 2026. Net revenues rose to $12.0 million, up 18.2% year over year, led by domestic core growth of 12.4% and international core growth of 59.1%, partly offset by a 35.0% decline in pharma services and clinical trials revenue.
Gross profit increased to $7.8 million with gross margin improving to 65.1% from 63.5%, while operating expenses grew 6.3% to $7.2 million. The company generated quarterly net income of $252,449, compared with a net loss in the prior-year quarter. For the first six months, net revenues were $23.8 million, up 20.1%, and the net loss narrowed to $554,629.
Cash and cash equivalents were $8.3 million at June 30, 2026, with net cash provided by operating activities of $230,776. KORU also has an undrawn $5.0 million revolving credit facility and a $5.0 million term loan, both amended in March 2026 to extend maturities and reduce interest-rate floors, and expects available liquidity to fund requirements for at least the next twelve months.
KORU Medical Systems, Inc. reported second quarter 2026 net revenues of $12.0 million, up 18.2% from $10.2 million a year earlier, driven by 12.4% domestic core growth and 59.1% international core growth. Pharma services and clinical trials revenue declined 35.0% to $0.6 million.
Gross profit rose to $7.8 million with gross margin improving to 65.1%, while operating expenses increased 6.3% to $7.2 million. Net income was $0.25 million, or $0.01 per diluted share, compared with a net loss of $0.21 million. Adjusted EBITDA grew to $0.9 million, or $0.02 per adjusted diluted share.
Cash and cash equivalents were $8.3 million as of June 30, 2026, after $0.5 million of cash usage in the quarter. The company acquired a connected monitoring technology asset and entered a multi-year supply agreement. Full-year 2026 guidance now calls for net revenues of $47.5–$48.5 million, gross margin of 62–64%, positive adjusted EBITDA, and year-end cash above $7.5 million. KORU also withdrew its Phesgo® 510(k) and refocused its U.S. oncology strategy on higher-volume molecules.
BlackRock, Inc. reports beneficial ownership of common stock of KORU MEDICAL SYSTEMS INC. BlackRock and certain of its subsidiaries and affiliates collectively hold 2,575,761 shares of KORU common stock, representing 5.6% of the class.
BlackRock has sole voting power over 2,537,482 shares and sole dispositive power over 2,575,761 shares, with no shared voting or dispositive power reported. Various underlying clients and investors have rights to dividends or sale proceeds, but no single such person is reported to hold more than five percent of KORU’s outstanding common shares. The filing is signed by a BlackRock managing director.
KALBERMATTEN ADAM R reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems, Inc. reported that President and CEO Adam R. Kalbermatten received a grant of 284,091 Performance Stock Units tied to long-term performance goals. According to the award terms, 213,068 units may vest based on a target for the company’s net sales growth on or prior to 12/31/2030, and 71,023 units may vest based on achieving a specified market capitalization target as of 12/31/2030. The award represents a performance-based equity incentive linked to both operating and market outcomes.
KALBERMATTEN ADAM R reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems reported that President and CEO Adam R. Kalbermatten received a grant of 286,697 Performance Stock Units, each tied to an equal number of common shares. These awards were made under his amended and restated employment agreement as part of equity-based compensation.
According to the performance terms, 215,023 units may vest based on achieving a target level of the company's net sales growth on or prior to 12/31/2030, and 71,674 units may vest based on reaching a specified company market capitalization at 12/31/2030. All 286,697 units are reported as directly held following this grant.
KORU Medical Systems director Edward Wholihan received a grant of 3,571 shares of Common Stock, valued at $4.20 per share. This is a compensation-related award reported as an acquisition, not an open-market purchase. After the grant, his direct ownership totals 51,312 shares.